{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:03:39Z","timestamp":1793232219008,"version":"4.5.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2021\/034\/TRP\/09\/Nanomedicine"],"award-info":[{"award-number":["NUHSRO\/2021\/034\/TRP\/09\/Nanomedicine"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2021\/097\/Startup\/13"],"award-info":[{"award-number":["NUHSRO\/2021\/097\/Startup\/13"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["23-0173-A0001"],"award-info":[{"award-number":["23-0173-A0001"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2023\/008\/NUSMed\/TCE\/LOA"],"award-info":[{"award-number":["NUHSRO\/2023\/008\/NUSMed\/TCE\/LOA"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2020\/133\/Startup\/08"],"award-info":[{"award-number":["NUHSRO\/2020\/133\/Startup\/08"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2022\/093\/T1\/Seed Sep\/06"],"award-info":[{"award-number":["NUHSRO\/2022\/093\/T1\/Seed Sep\/06"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["MOE 000387 00"],"award-info":[{"award-number":["MOE 000387 00"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["MOE MOET32023 004"],"award-info":[{"award-number":["MOE MOET32023 004"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH 001740 01"],"award-info":[{"award-number":["MOH 001740 01"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001334-00"],"award-info":[{"award-number":["MOH-001334-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH 001500 00"],"award-info":[{"award-number":["MOH 001500 00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH 001609 00"],"award-info":[{"award-number":["MOH 001609 00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["CG21APR1005"],"award-info":[{"award-number":["CG21APR1005"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001388-00"],"award-info":[{"award-number":["MOH-001388-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001483-00"],"award-info":[{"award-number":["MOH-001483-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH 001254 01"],"award-info":[{"award-number":["MOH 001254 01"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025178","name":"OpenAI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025178","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","award":["NUS-P21"],"award-info":[{"award-number":["NUS-P21"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","award":["000352 00"],"award-info":[{"award-number":["000352 00"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jconrel.2025.114543","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:17:27Z","timestamp":1765556247000},"page":"114543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Tumor targeted radionuclide-nanomedicine for clinical translation: From carrier innovation to precision therapy"],"prefix":"10.1016","volume":"390","author":[{"given":"Zhenni","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyao","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114543_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0010","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0020","doi-asserted-by":"crossref","first-page":"eabb3631","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114543_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.2006","article-title":"Nanoscale radiotheranostics for cancer treatment: from bench to bedside","volume":"16","author":"Jiao","year":"2024","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0035","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114543_bb0040","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1007\/s00259-023-06384-0","article-title":"PSMA-based alpha therapy in prostate cancer","volume":"50","author":"Sathekge","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.114543_bb0045","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114543_bb0050","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumors: the value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.114543_bb0060","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1158\/0008-5472.CAN-20-3822","article-title":"Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of Trastuzumab and enhance T-DM1 efficacy","volume":"81","author":"Bordeau","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114543_bb0065","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1038\/s41467-020-19498-y","article-title":"Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates","volume":"11","author":"Lu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114543_bb0070","first-page":"1191","article-title":"A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier","volume":"31","author":"Fujimori","year":"1990","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114543_bb0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0085","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2310\/7290.2010.00031","article-title":"Nanoparticles for biomedical imaging: fundamentals of clinical translation","volume":"9","author":"Choi","year":"2010","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.114543_bb0095","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114543_bb0100","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","article-title":"Pharmacokinetics and biodistribution of nanoparticles","volume":"5","author":"Li","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114543_bb0105","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumors","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2025.114543_bb0110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114543_bb0115","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","article-title":"Smart cancer nanomedicine","volume":"14","author":"van der Meel","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0120","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered nanoparticles for drug delivery in cancer therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jconrel.2025.114543_bb0125","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.addr.2010.07.009","article-title":"Nanoparticle-based theranostic agents","volume":"62","author":"Xie","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114543_bb0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1039\/C1NR11277E","article-title":"Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives","volume":"4","author":"Choi","year":"2012","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.114543_bb0135","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: combining imaging and therapy","volume":"22","author":"Kelkar","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.114543_bb0140","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2967\/jnumed.114.146019","article-title":"Theranostic nanoparticles","volume":"55","author":"Chen","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0145","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1039\/D2RA07863E","article-title":"Cancer nanomedicine: a review of nano-therapeutics and challenges ahead","volume":"13","author":"Nirmala","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2025.114543_bb0150","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2217\/nnm.10.113","article-title":"The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting","volume":"5","author":"Huynh","year":"2010","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.jconrel.2025.114543_bb0155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114543_bb0165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-040210-162544","article-title":"Nanoparticle delivery of cancer drugs","volume":"63","author":"Wang","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0170","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumors","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2025.114543_bb0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12645-023-00165-y","article-title":"Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts","volume":"14","author":"Goel","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0185","doi-asserted-by":"crossref","first-page":"16974","DOI":"10.1021\/acsnano.1c09139","article-title":"Nanoparticles for cancer diagnosis, radionuclide therapy and theranostics","volume":"15","author":"Llop","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.114543_bb0195","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.7150\/thno.38069","article-title":"Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics","volume":"10","author":"Mi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114543_bb0200","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ejpb.2008.09.026","article-title":"Multifunctional and stimuli-sensitive pharmaceutical nanocarriers","volume":"71","author":"Torchilin","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2025.114543_bb0205","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41401-020-0448-9","article-title":"Cancer nanomedicine meets immunotherapy: opportunities and challenges","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2025.114543_bb0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114543_bb0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114543_bb0225","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/imt-2018-0029","article-title":"Gold nanoparticles-mediated photothermal therapy and immunotherapy","volume":"10","author":"Liu","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2025.114543_bb0230","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1016\/j.biomaterials.2014.03.065","article-title":"Gold nanoshells-mediated bimodal photodynamic and photothermal cancer treatment using ultra-low doses of near infra-red light","volume":"35","author":"Vankayala","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114543_bb0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.matt.2020.04.022","article-title":"Germanene-based theranostic materials for surgical adjuvant treatment: inhibiting tumor recurrence and wound infection","volume":"3","author":"Feng","year":"2020","journal-title":"Matter"},{"key":"10.1016\/j.jconrel.2025.114543_bb0405","doi-asserted-by":"crossref","first-page":"25599","DOI":"10.1021\/acsami.1c02155","article-title":"Calcium carbonate core-shell particles for incorporation of 225Ac and their application in local \u03b1-radionuclide therapy","volume":"13","author":"Muslimov","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.114543_bb0590","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41467-025-57263-1","article-title":"Convection enhanced delivery of rhenium 186Re Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial","volume":"16","author":"Brenner","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114543_bb0595","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1021\/acsnano.4c18489","article-title":"Preclinical and first-in-human study of a compact radionuclide labeled self-assembly nanomedicine for chemo-radio-theranostics of cancer","volume":"19","author":"Xiong","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.114543_bb0600","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","article-title":"First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Zang","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.114543_bb0395","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2967\/jnumed.122.264857","article-title":"Low-dose, prospective study of 177Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"64","author":"Wang","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0605","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2967\/jnumed.120.242263","article-title":"(177)Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer","volume":"61","author":"Zang","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0610","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0615","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.120.253062","article-title":"Impact of 68Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas","volume":"62","author":"R\u00f6hrich","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0440","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.122.265355","article-title":"Evaluation of 134Ce\/134La as a PET imaging theranostic pair for 225Ac \u03b1-radiotherapeutics","volume":"64","author":"Bobba","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0620","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2967\/jnumed.119.236265","article-title":"177Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer","volume":"61","author":"Hernandez","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0250","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.114543_bb0255","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.114543_bb0260","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2967\/jnumed.123.265952","article-title":"SNMMI consensus statement on patient selection and appropriate use of 177Lu-PSMA-617 radionuclide therapy","volume":"64","author":"Hope","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0275","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2967\/jnumed.123.266619","article-title":"Safety and efficacy of para-aminohippurate coinfusion for renal protection during peptide receptor radiotherapy in patients with neuroendocrine tumors","volume":"65","author":"Moraitis","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0280","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2967\/jnumed.106.037069","article-title":"Theoretic criteria for antibody penetration into solid tumors and micrometastases","volume":"48","author":"Thurber","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0285","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-023-01030-0","article-title":"Fc-engineered monoclonal antibodies to reduce off-target liver uptake","volume":"13","author":"Mangeat","year":"2023","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.jconrel.2025.114543_bb0290","article-title":"Antibody-incorporated nanomedicines for cancer therapy","volume":"34","author":"Wu","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.114543_bb0295","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114543_bb0300","doi-asserted-by":"crossref","first-page":"2312169","DOI":"10.1002\/adma.202312169","article-title":"Nanomedicine tumor targeting","volume":"36","author":"Lammers","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.114543_bb0305","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41467-017-00600-w","article-title":"Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114543_bb0310","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41578-023-00552-2","article-title":"The protein corona from nanomedicine to environmental science","volume":"8","author":"Mahmoudi","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2025.114543_bb0315","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41563-023-01630-0","article-title":"The exit of nanoparticles from solid tumors","volume":"22","author":"Nguyen","year":"2023","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2025.114543_bb0320","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","article-title":"Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial","volume":"15","author":"Carpentier","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114543_bb0325","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41467-024-48326-w","article-title":"Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas","volume":"15","author":"Arrieta","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114543_bb0330","doi-asserted-by":"crossref","first-page":"2402361","DOI":"10.1002\/advs.202402361","article-title":"Engineered antibodies as cancer radiotheranostics","volume":"11","author":"Wei","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.114543_bb0335","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2967\/jnumed.122.265338","article-title":"Single-time-point imaging for dosimetry after 177Lu-DOTATATE: accuracy of existing methods and novel data-driven models for reducing sensitivity to time-point selection","volume":"64","author":"Wang","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0340","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2967\/jnumed.122.264594","article-title":"Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy","volume":"64","author":"Brosch-Lenz","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0345","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12951-024-02520-6","article-title":"Development of 225Ac-doped biocompatible nanoparticles for targeted alpha therapy","volume":"22","author":"Toro-Gonz\u00e1lez","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0350","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40658-024-00635-1","article-title":"Quantitative SPECT\/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas","volume":"11","author":"Tulik","year":"2024","journal-title":"EJNMMI Phys."},{"key":"10.1016\/j.jconrel.2025.114543_bb0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","article-title":"Implementing ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives","volume":"9","author":"Hooijman","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.jconrel.2025.114543_bb0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41565-023-01507-y","article-title":"Multivalent insulin receptor activation using insulin-DNA origami nanostructures","volume":"19","author":"Spratt","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0365","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1038\/s41467-020-18603-5","article-title":"Combinatorial entropy behaviour leads to range selective binding in ligand-receptor interactions","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114543_bb0370","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejrad.2017.05.029","article-title":"Clinical evaluation of whole-body oncologic PET with time-of-flight and point-spread function for the hybrid PET\/MR system","volume":"93","author":"Shang","year":"2017","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0375","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2017.24","article-title":"Rethinking cancer nanotheranostics","volume":"2","author":"Chen","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2025.114543_bb0380","doi-asserted-by":"crossref","first-page":"243","DOI":"10.7150\/thno.14322","article-title":"Chemical conjugation of Evans blue derivative: a strategy to develop long-acting therapeutics through albumin binding","volume":"6","author":"Chen","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114543_bb0385","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy","volume":"63","author":"Xu","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0390","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","article-title":"177Lu-labeled albumin-binder-conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio","volume":"62","author":"Kuo","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117589","article-title":"Preparation and evaluation of a novel albumin-binding heterodimer therapeutic radiopharmaceutical with remarkable tumor accumulation and retention","volume":"290","author":"Yang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114543_bb0410","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1021\/acs.bioconjchem.2c00190","article-title":"H(2)BZmacropa-NCS: a bifunctional chelator for actinium-225 targeted alpha therapy","volume":"33","author":"Kadassery","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.114543_bb0415","doi-asserted-by":"crossref","first-page":"20699","DOI":"10.1021\/acs.inorgchem.3c01983","article-title":"Equilibrium thermodynamics of macropa complexes with selected metal isotopes of radiopharmaceutical interest","volume":"62","author":"Blei","year":"2023","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jconrel.2025.114543_bb0420","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41392-023-01654-7","article-title":"Multifunctional mesoporous silica nanoparticles for biomedical applications","volume":"8","author":"Xu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114543_bb0425","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1021\/acsanm.0c01427","article-title":"177Lu-labeled Eu-doped mesoporous SiO2 nanoparticles as a theranostic radiopharmaceutical for colorectal cancer","volume":"3","author":"Viana","year":"2020","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.jconrel.2025.114543_bb0435","doi-asserted-by":"crossref","first-page":"16577","DOI":"10.1021\/acsnano.3c13213","article-title":"Precision atomistic structures of actinium\u2212\/radium\u2212\/barium-doped lanthanide nanoconstructs for radiotherapeutic applications","volume":"18","author":"Goswami","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.114543_bb0445","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1021\/acsnano.8b02400","article-title":"Highly effective radioisotope cancer therapy with a non-therapeutic isotope delivered and sensitized by nanoscale coordination polymers","volume":"12","author":"Chao","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.114543_bb0450","doi-asserted-by":"crossref","first-page":"12250","DOI":"10.1021\/nn506130t","article-title":"Activatable hyaluronic acid nanoparticle as a theranostic agent for optical\/photoacoustic image-guided photothermal therapy","volume":"8","author":"Zhang","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.114543_bb0455","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1021\/jacs.1c12935","article-title":"Stimuli-responsive macrocyclization scaffold allows in situ self-assembly of radioactive tracers for positron emission tomography imaging of enzyme activity","volume":"144","author":"Lin","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2025.114543_bb0460","doi-asserted-by":"crossref","first-page":"0015","DOI":"10.34133\/bmr.0015","article-title":"Nanodrug delivery systems in antitumor immunotherapy","volume":"28","author":"Guo","year":"2024","journal-title":"Biomater. Res."},{"key":"10.1016\/j.jconrel.2025.114543_bb0465","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114543_bb0470","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2967\/jnumed.112.115840","article-title":"A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry","volume":"54","author":"Zeglis","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114543_bb0475","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-18-1650","article-title":"Leveraging bioorthogonal click chemistry to improve 225Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma","volume":"25","author":"Poty","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114543_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2025.109051","article-title":"ImmunoPET for mesothelin positive tissues using bio-orthogonal in-vivo click chemistry","volume":"148-149","author":"Pratt","year":"2025","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0485","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cbpa.2020.09.002","article-title":"Recent developments in bioorthogonal chemistry and the orthogonality within","volume":"60","author":"Smeenk","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0490","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1021\/jacsau.3c00843","article-title":"Enabling universal access to rapid and stable tetrazine bioorthogonal probes through triazolyl-tetrazine formation","volume":"4","author":"Yang","year":"2024","journal-title":"JACS Au."},{"key":"10.1016\/j.jconrel.2025.114543_bb0495","doi-asserted-by":"crossref","DOI":"10.3390\/ph15060685","article-title":"Recent advances in the development of tetrazine ligation tools for pretargeted nuclear imaging","volume":"15","author":"Garcia-Vazquez","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2025.114543_bb0500","doi-asserted-by":"crossref","first-page":"28316","DOI":"10.1073\/pnas.2009960117","article-title":"Harnessing 64Cu\/67Cu for a theranostic approach to pretargeted radioimmunotherapy","volume":"117","author":"Kein\u00e4nen","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.114543_bb0505","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41596-023-00825-8","article-title":"Click chemistry: a transformative technology in nuclear medicine","volume":"18","author":"Bauer","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2025.114543_bb0510","doi-asserted-by":"crossref","first-page":"eaba3546","DOI":"10.1126\/sciadv.aba3546","article-title":"Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer","volume":"6","author":"Yi","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.114543_bb0515","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114543_bb0520","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114543_bb0525","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","article-title":"Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114543_bb0530","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1038\/s41467-024-54293-z","article-title":"Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy","volume":"15","author":"Choi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114543_bb0535","doi-asserted-by":"crossref","first-page":"2400228","DOI":"10.1002\/adma.202400228","article-title":"Spatiotemporal-controlled NIR-II immune agonist sensitizes cancer immunotherapy","volume":"36","author":"Guo","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.114543_bb0540","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","article-title":"Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors","volume":"22","author":"Catanzaro","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0555","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.114543_bb0560","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.7150\/thno.92742","article-title":"Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce\/225Ac-Macropa-PEG(4)-YS5","volume":"14","author":"Bobba","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114543_bb0565","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1039\/D0CS00384K","article-title":"Radiolabelling of nanomaterials for medical imaging and therapy","volume":"50","author":"Pellico","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2025.114543_bb0570","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1021\/acs.chemrev.3c00028","article-title":"Recent advances in DNA origami-engineered nanomaterials and applications","volume":"123","author":"Zhan","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.114543_bb0575","doi-asserted-by":"crossref","first-page":"27364","DOI":"10.1038\/s41598-024-78399-y","article-title":"DNA origami drives gene expression in a human cell culture system","volume":"14","author":"Oh","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.114543_bb0580","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1158\/1078-0432.CCR-24-3098","article-title":"Pretargeted trop-2 immunoPET for rapid, selective detection of pancreatic tumors","volume":"31","author":"Pratt","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114543_bb0625","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae - the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114543_bb0630","series-title":"Albumin in Medicine: Pathological and Clinical Applications","first-page":"101","article-title":"Nanoparticle albumin-bound paclitaxel (Abraxane\u00ae)","author":"Desai","year":"2016"},{"key":"10.1016\/j.jconrel.2025.114543_bb0635","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1039\/D3LC00821E","article-title":"Microfluidic synthesis of lipid-based nanoparticles for drug delivery: recent advances and opportunities","volume":"24","author":"Mehraji","year":"2024","journal-title":"Lab Chip"},{"key":"10.1016\/j.jconrel.2025.114543_bb0640","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114543_bb0645","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:26:23Z","timestamp":1781702783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925011575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":118,"alternative-id":["S0168365925011575"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114543","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor targeted radionuclide-nanomedicine for clinical translation: From carrier innovation to precision therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114543"}}